Putting Science to Work

In the News

  • Syngene International acquires Strand Life Sciences’s assets.

    Live Mint-22/09/2016. Syngene is constantly looking for new opportunities to expand its service offerings and plans to expand into areas such as NGS, translational R&D, predictive toxicology and pre-emptive target validation services, all of which require strong bioinformatics capabilities...

  • Syngene International Commissions Dedicated R&D Center for Amgen.

    Financial Times-06/09/2016. The state-of-the-art dedicated center will be staffed by a team of more than 100 highly qualified Syngene scientists, working in close association with Amgen researchers around the world on the discovery and development of innovative medicines...

  • Syngene Posts 28% Rise In Q1 Profit

    Profit NDTV-21/07/2016. Standalone total income from operations also rose to Rs 274.5 crore for the quarter ended June, 2016 as against Rs 233.7 crore for the year-ago..

  • Syngene Q4 profit up 18% to Rs 66 crore

    Mint-27/04/2016. The profit was notched up on a 28% increase in Syngene’s revenue to Rs334 crore from Rs254 crore

  • Syngene Q4 profit up 18% to Rs 66 crore

    Mint-27/04/2016. The profit was notched up on a 28% increase in Syngene’s revenue to Rs334 crore from Rs254 crore

  • Syngene Q3 profit jumps 31% to Rs 59 cr.

    Business Standard-21/01/2016. Syngene reported a 31% jump in third quarter profits to Rs 59 crore and 23% growth in revenues to Rs 281 crore on improved business from its global clients to help build new drug discovery.

  • India has 'natural potential to grow' in CRO space, says Syngene CEO

    Outsourcing Pharma-14/01/2016. An exclusive interview with Peter Bains- CEO ,Syngene International Ltd -

  • Syngene appoints Jonathan Hunt as CEO-designate.

    Business Today-05/01/2016. Syngene appoints Jonathan Hunt as CEO-designate. Mr Hunt to take charge post retirement of current CEO Peter Bains. Mr Bains will continue as a member of the Syngene Board.

  • India price advantage helped Boost Business

    NDTV- 22/11/2015. Peter Bains, director and CEO at Syngene International, told NDTV that it witnessed strong growth across its business verticals in the second quarter, which was supported by significant cost advantage in India.

  • Syngene Story

    ET-NOW - 03/10/2015. An exclusive interview with Kiran Mazumdar Shaw, Peter Bains and Manoj Nerurkar on Syngene's operations and journey so far at the sprawling Syngene campus.

Discovery Chemistry Discovery Biology Safety Assessment Large Molecule Development Chemical Development Formulation Development Stability Studies Polymer Research Integrated Discovery & Development Clinical Development Services Bioinfomatics Antibody Drug Conjugates Oligonucleotide Synthesis Contact Us

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

Social Widget